Overview

Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery

Status:
NOT_YET_RECRUITING

Trial end date:
2030-08-01

Target enrollment:

Participant gender:

Summary

To explore the non-inferiority of the 2y-OS rate of tislelizumab combined with chemotherapy after sequential CRT in the treatment of resectable esophageal squamous cell carcinoma compared with the surgical group

Phase:

PHASE2

Details

Lead Sponsor:

Fujian Cancer Hospital

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Cisplatin
nedaplatin
Radiation
Surgical Procedures, Operative
tislelizumab